(Total Views: 662)
Posted On: 07/10/2020 10:37:12 PM
Post# of 154011
Re: StinkyPennies #42117
StinkyPennies, the source of your confusions is the Montefiore papers.
The docs at Montefiore have already had one article published in NEJM.
The first Montefiiore paper, which was published weeks ago, was not a "paper" but was in fact a letter to the editor.
Prior to to the NEJM publication, Pourhassan said something along the lines of "a paper will be published in NEJM next week".
It was a letter-to-the-editor from the Montefiore doces (at least 15 authors) describing about 10 covd19 patients treated at Montefiore. I think six of these patients received leronlimab as part of their treatment course.
Patterson's paper was submitted for publication at around the same time.
The Montefiore paper was not a paper, just a letter so it doesn't get any peer review, it just gets published.
I think you and your sources are confused because you have incorrectly identified Pourhassan's Montefiore paper comments as Patterson paper comments.
The docs at Montefiore have already had one article published in NEJM.
The first Montefiiore paper, which was published weeks ago, was not a "paper" but was in fact a letter to the editor.
Prior to to the NEJM publication, Pourhassan said something along the lines of "a paper will be published in NEJM next week".
It was a letter-to-the-editor from the Montefiore doces (at least 15 authors) describing about 10 covd19 patients treated at Montefiore. I think six of these patients received leronlimab as part of their treatment course.
Patterson's paper was submitted for publication at around the same time.
The Montefiore paper was not a paper, just a letter so it doesn't get any peer review, it just gets published.
I think you and your sources are confused because you have incorrectly identified Pourhassan's Montefiore paper comments as Patterson paper comments.
(2)
(0)
